Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics

Nirmatrelvir/ritonavir (N/R) is one of the most effective antiviral drugs against SARS-CoV-2. The preclinical development, pharmacodynamics and pharmacokinetics of N/R are reviewed herein. Randomized clinical trials have been conducted exclusively with pre-Omicron variants of concern, but in vitro s...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, Daniele, McConnell, Scott, Shoham, Shmuel, Casadevall, Arturo, Maggi, Fabrizio, Antonelli, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806926/
https://www.ncbi.nlm.nih.gov/pubmed/36603694
http://dx.doi.org/10.1016/j.ijantimicag.2022.106708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806926/
https://www.ncbi.nlm.nih.gov/pubmed/36603694
http://dx.doi.org/10.1016/j.ijantimicag.2022.106708

Ejemplares similares